Another dangerous combination for hypoglycemic coma: concurrent use of sibutramine and lorazepam.
نویسندگان
چکیده
Another dangerous combination for hypoglycemic coma: concurrent use of sibutramine and lorazepam Sir, With increasing demands to treat obesity in both medical and psychological aspects, many drugs are developed to lower human body weight. Those widely used anti-obesity drugs, such as olistat and sibutramine, are generally safe. But serious adverse effects could be developed when it is concurrently used with other medications. We report a patient who developed hypoglycemic coma due to concurrent use of sibutramine and lorazepam. A 32-year-old woman presented to the emergency department because of disturbed consciousness and an episode of generalized seizure attack. On arrival, she was comatose with a blood pressure 108/ 58 mmHg, pulse rate 96 beat/min, respiration rate 20 breath/min and body temperature 35.6 C. The result of a focused neurologic examination was normal. A capillary blood glucose measurement was 27 mg/dl. She regained consciousness promptly after treated with bolus of 50% dextrose and continuous infusion of 10% dextrose. She had no history of systemic illness. She was treated with sibutramine 10 mg per day by another hospital due to overweight. She developed insomnia, for which she used lorazepam 2 mg on as needed basis. Her families stated that she complied poorly with follow-up program and had no food intake for less than 12 h prior to admission. Her BMI was 22 at this presentation. The laboratory data including complete blood count, liver function tests and serum creatinine were normal. The serum ethanol level was zero, but she had a positive urinary test for benzodiazepine. An endocrinologist was consulted and she was admitted. At the ward, her serum glucose levels were checked every hour and no further hypogly-cemic episode was noted. Her albumin and total protein were 3.8 and 6.5 g/dl, respectively. She had a insulin level of 5.2 mU/ml (normal range, 5–25 mU/ ml), a negative urinary sulfonylurea screening test and a suppressible C-peptide suppression test. She had a normal serum cortisol level of 21.66 mg/dl at 8:00 a.m. and a normal human growth hormone of 0.1 ng/ml. Her thyroid function panel was also normal (triiodothyronine 89.26 ng/dl; thyroid-stimulating hormone 1.62 mU/ml; and free thyroxine 1.61 ng/dl). The magnetic resonance imaging of the abdomen showed no pancreatic mass. She was discharged on the 5th hospital day. On follow-up at clinic for 6 months, she no longer had hypoglyce-mic episode. This young woman who used sibutramine and lorazepam concurrently developed hypoglycemic coma after …
منابع مشابه
Effects of sibutramine in obese female subjects with type 2 diabetes and poor blood glucose control.
OBJECTIVE In this study, we evaluated the efficacy of sibutramine in combination with hypoglycemic drugs in obese type 2 diabetic women whose glucose levels were poorly regulated. RESEARCH DESIGN AND METHODS Female patients with type 2 diabetes, poorly controlled glucose levels, and HbA(1c) >8% were randomly assigned to one of two groups. In addition to their prescribed hypoglycemic agents (m...
متن کاملInsulin Potentiation Therapy
Insulin potentiation therapy (IPT) is an unproven adjunct to cancer chemotherapy that uses insulin followed by sub-therapeutic doses of chemotherapy or other medications well below their proven efficacy. Theoretically, IPT boosts the pharmacologic efficacy of medications by increasing uptake into the cells of the body. During IPT enough insulin is given to induce hypoglycemic shock (perspiratio...
متن کاملAnalysis of Risk Factors for Hypoglycemic Coma in 194 Patients with Type 2 Diabetes
BACKGROUND The present study was conducted to analyze possible risk factors in patients with type 2 diabetes who are in hypoglycemic coma. MATERIAL AND METHODS A total of 194 patients with type 2 diabetic hypoglycemic coma who were admitted to our hospital between January 2010 and January 2016 were included. The patients were all in coma on admission, and their blood glucose levels were lower t...
متن کاملClinical characteristics of type 1 diabetic patients with and without severe hypoglycemia.
OBJECTIVE To investigate the frequency of severe hypoglycemia (SH) and hypoglycemic coma and to identify clinical and behavioral risk indicators in a nonselected population of type 1 diabetic patients. RESEARCH DESIGN AND METHODS This study involved a retrospective clinical survey of 195 consecutive patients using a questionnaire addressing the frequency of SH (i.e., help from others required...
متن کاملComa probably induced by lorazepam–valproate interaction
Both valproate (VPA) and lorazepam (LZP) are primarily cleared from the body by glucuronidation. Concomitant administration of VPA has been reported to reduce the elimination of LZP. However, it remains unknown whether this drug interaction is clinically significant. We report a patient with epilepsy who showed that VPA-LZP interaction could result in severe encephalopathy such as coma.
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
عنوان ژورنال:
- QJM : monthly journal of the Association of Physicians
دوره 101 3 شماره
صفحات -
تاریخ انتشار 2008